Please try another search
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Anna Moore | 61 | 2016 | Co-Founder, Scientific Advisor & Member of Scientific Advisory Board |
Dejan Juric | - | 2021 | Member of Advisory Board |
Raghu Kalluri | - | - | Member of Advisory Board |
Oliver Steinbach | - | - | Member of Advisory Board |
G. Susan Srivatsa | - | - | Member of Advisory Board |
Keith T. Flaherty | 53 | - | Member of Advisory Board |
George Calin | - | - | Member of Advisory Board |
Raul Mostoslavsky | - | - | Member of Advisory Board |
Magda Marquet | 65 | 2021 | Independent Director |
Erik Manting | 53 | 2020 | Independent Director |
Betsabeh Madani Hermann | - | - | Member of Advisory Board |
Lubomir Nechev | - | 2021 | Member of Advisory Board |
Philippe P. Calais | 65 | 2018 | Executive Chairman of the Board |
Dmitry Samarsky | 57 | - | Member of Advisory Board |
Mehmet Yigit | - | - | Member of Advisory Board |
Jerome M. Lewis | 75 | - | Member of Advisory Board |
John B. Henneman | 62 | - | Member of Advisory Board |
Frank J. Slack | - | 2022 | Member of Advisory Board |
Thomas A. Fitzgerald | 72 | 2018 | Interim CEO, CFO, President, VP of Administration & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review